Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - cyproterone acetate - tablet - cyproterone acetate 50 mg - sex hormones and modulators of the genital system

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - cyproterone acetate - tablet - cyproterone acetate 50 milligram(s) - sex hormones and modulators of the genital system

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - cyproterone acetate - tablets - 50 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - cyproterone acetate ethinylestradiol - tablets - 2mg/35ug %v/v

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cyproterone acetate -

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; maize starch - inoperable prostatic carcinoma. because of its anti-androgenic effect cyprostat is indicated for the treatment of inoperable prostatic carcinoma in patients who have failed primary hormonal manipulation or who are at risk from cardiovascular disease and/or intolerant of oestrogen therapy. indications as at 18 may 2005 : inoperable prostatic carcinoma. * to suppress flare with initial lhrh analogues therapy. * in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. * in the treatment of hot flushes in pateinets treated with lhrh analogues or who have had orchiectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; povidone - inoperable prostatic carcinoma. because of its anti-androgenic effect androcur is indicated for the treatment of inoperable prostatic carcinoma in patients who have failed primary hormonal manipulation or who are at risk from cardiovascular disease and/or who are intolerant of oestrogen therapy. indications as at 1 june 1995: inoperable prostatic carcinoma to suppress 'flare' with initial lhrh analogue therapy; in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.